Member Info for GlenFidrich

Don't worry about it. It's just Bozo and his friends. In a way, their constant scaremongering and denigration of PYC is, for me, a huge buy signal. They only tend to infiltrate chat boards when they see the chance to undermine confidence in weak holders and prey on those trading for short term profit. Witness Utah, who boasted recently that he could continually trade PYC for 10% profit, not realizing that often the spread between the bid and ask is 11%! It's these kind of clowns that we're dealing with, Kid, so best to consign them to the circular filing cabinet.

Looking like a period of consolidation is happening - no bad thing, actually - with support around 6.4p and resistance around the 7.4p mark. I guess we have to allow the MMs their 10%-15% margins. Personally, I don't day trade this share (or any other share, for that matter), but I do feel we are close to a great buying opportunity/quick trade for those so inclined. Volume remains pitifully low which is why yesterday's drop was so frustrating. Hang in there, chaps! These frustrating periods are often the precursor to (at least) 50% rises, based on previous history. So, 10p should not be that far away, AIMHO.

Oh Lord, have mercy! Baron Duffer doesn't know what news is due, but is pontificating on the SP "within a month or so". Ah well, thanks for the insight, Baron. I think I'll stick with the facts (as often presented by riddler). Jeez, I think Billy Smart's must really be in town - the clowns are back. Give me strength!

https://lifescivc.com/2021/03/selective-allosteric-tyk2-inhibitors/
I imagine this article may well have been posted in the past, but I for one missed it! It is, nonetheless, a good summary of the state of play re: TYK2 inhibitors, their safety profile (or otherwise), and their future potential (psoriasis alone is a $4 billion market). All in all, a simple and straight-forward read (or re-read) which I found accessible and interesting.

Do you have the link, as I can't seem to find it on the Agile website (https://www.agiletrial.net)? Cheers.

How did your VAL trade pan out, lol!

No need to apologize, milord, just me ranting. It must be the Rockfords!

Steve, there have been 3 trades today (as far as I can see) - 72k in buys, and 8.3k in sells - and you're fretting over the direction in which this share is going? Grow up! PYC is expanding its workforce. Does this not tell you something?? Jeez, I'm surrounded by idiots. Beam me up, Scotty, ffs!

...before Lord Lucan states the bleeding obvious.

By 2015, the cost to the UK government of their involvement in the wars in Iraq and Afghanistan totaled almost 30 billion pounds. God knows the figure for the intervening years since then, but look how that's turned out. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/494526/FOI2015-08279-Cost_of_the_wars_in_Iraq_and_Afghanistan.pdf
15 billion pounds for promising drug candidates in the areas of cancer, autoimmune disease, and Covid-19 sounds reasonable to me, especially as they'll likely save lives. Having said that, I'd settle for 2 billion up front for sure ; )

...have seen strategic additions to the team. The confidence to continue expanding the business via such additions bodes well for the future of PYC, imo.

Almost two months have passed and yet we still await news re: AGILE. Something about "Nero fiddles while Rome burns" springs to mind. I can't fathom it myself, unless T/O discussions are underway?

For anyone contemplating an investment in Physiomics, I thought the following article might be a good starting point in understanding the general area that Physiomics is operating in, and why the future potential is enormous.
https://www.datarevenue.com/en-blog/artificial-intelligence-in-medicine
Good luck all!

There were roughly 21m shares traded today, right? Some were buys, but probably a majority were sells, right? But less than 0.7% of shares in issue changed hands today and we're down almost 10%? Sorry, but something just doesn't add up unless, of course, today was just one concerted attempt to scare people into selling. My advice, fwiw, is don't be fooled! Keep the faith!

Couldn't agree more, Bobbler. The last RNS was constructed in a revealing way, in my opinion. Each string to Sareum's bow was dealt with individually:
1) SDC-1801 for treating symptoms of Covid-19 - 4 paragraphs.
2) SDC-1801 (autoimmune diseases) - 1 paragraph.
3) SDC-1802 (cancer immunotherapy) - 2 paragraphs.
4) Licensed Programme - SRA737: A Selective Chk1 inhibitor - 2 paragraphs.
I know it may be a slightly simplistic way of looking at it, but I do think Covid is still the main focus, even though Sareum's involvement is more by chance than design. I can't fathom the reasons for the apparent delay, however - initial "encouraging" results were published on July 1st, and we're now 23rd August. Governmental protocols/bureaucracy? Takeover/partnership talks? Who knows? I think, also, that the HNWIs involvement with Sareum is Covid related, somehow. So, all in all, I think news relating to Covid will be the next catalyst that propels us forward. Agile for me would be ideal, as it would fast track SDC-1801 for Covid, but surely as part of the process there would also be some overlapping with regard to autoimmune indications, thereby killing two birds with one stone, so-to-speak?

Hardly a mass exodus (with six and a half million shares traded so far), unless you're a rat that is!

Thommo, I take issue with your "SAR won’t get a seat at the COVID table now" statement. I think the exact opposite. Read the most recent RNS. "The project found that SDC-1801 reduced the levels of cytokines associated with Acute Respiratory Distress Syndrome (ARDS) in human lung cells infected with SARS-CoV-2 and demonstrated a profile that was superior to the anti-inflammatory steroid dexamethasone and similar to baricitinib, a JAK1/JAK2 inhibitor." What more can Sareum do to demonstrate the potential of SDC-1801 in treating Covid patients? It is, in my view, inconceivable that these outstanding results will just be ignored. I imagine the powers that be in government, as well as large pharmas, are pouring over the data as we speak. It was also the first item on the "Operational Highlights" section of the RNS, a hint perhaps at where most of the BoD's time and energy are being focused at present. My only concern is the speed at which all of this is moving, given the obvious paralyzing effect Covid is having on economies around the world, not to mention the ongoing health crises. I understand there are certain protocols that need to be followed, but I thought the whole point of Agile was to fast-track drugs through the early clinical phases. A sense of urgency seems to be wanting here, which is a shame.

Good question. Down 10% on volume of 17.1m shares (around 0.5% of shares in issue)! Go figure. Time for a top up methinks.

Good strategy. I guess many of us here have been 'under water' in the past, and will know the feeling of having invested in a share seemingly in free fall. The trick with SAR is not to panic, hold, and (if you can) buy the dips. You're absolutely right when you say the market doesn't know how to value our IP, hence the almost daily ups and downs recently. We're in uncharted territory - this is cutting edge science and maybe the future of biologics - and the MMs don't have a clue. Hold tight.

TM's final "to build a robust data package to support our ongoing partnering activities for these exciting and differentiated assets" speaks volumes, in my opinion.